Radioprotective effects of troxerutin against gamma irradiation in V79 cells and mice

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 10, 2011, Pages 2593-2596

  Ping, Xu ^a   Junqing, Jia ^a   Junfeng, Jia ^a   Enjin, Jiang ^b  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Apoptosis rate; Cell survival; Radioprotection; Survival rate; Troxerutin; V79 cells

Indexed keywords

EID: 84858166096     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Auteri A, Blardi P, Frigerio C, et al (1990). Pharmacodynamics of troxerutine in patients with chronic venous insufficiency: correlations with plasma drug levels. Int J Clin Pharmacol Res, 10, 235-41.
2. Biosseau M, Freyburger G, Beylot C, et al (1986). Erythrocyte aggregation and parameters hemorheologic at the insufficiency venous influence of the troxerutin. Arteries Veins, 5, 231-4.
3. Blasig IE, Loewe H, Elbert B (1987). Radical trapping and lipid peroxidation during myocardial reperfusion injury-radical scavenging by troxerutin in comprision to mannitol. Biomed Biochim Acta, 47, S539-44.
4. Blasig IE, Loewe H, Elbert B (1988). Effect of troxerutin and methionine on spin trapping of free oxy-radicals. Biomed Biochim Acta, 47, S252-5.
5. Boisseu MR, Taccoen A, Garreau C, et al (1995). Fibrinolysis and hemorheology in chronic venous insufficiency: a double blind study of troxerutin efficiency. J Cardiovasc Surg, 36, 369-74.
6. Cesarone MR, Belcaro G, Brandolini R, et al (2003). The lonflit4-Venorutin Study:a randomized trial - prophylaxis of flight-edema in venous patients. Angiology, 54, 137-42.
7. Cosarone MR, Belcaro G, Geroulakos G, Griffin M, et al (2003). Flight microangiopathy on long-haul flights:prevention of edema and microcirculation lterations with venoruton. Clin Appl Thromb Hemost, 9, 109-14.
8. Dharmendra KM, Veena PS, Cherupally KK (2004). Radioprotection of normal tissues in tumor-bearing mice by troxerutin. Radiat Res, 2, 221-8.
9. Dumont FJ, Le Roux A, Bischoff P (2010). Radiation countermeasure agents: an update. Expert Opin Ther Pat, 20, 73-101.
10. Glacet-Bernard A, Coscas G, Chabanel A, et al (1994). A randomized, doublemasked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol, 118, 421-9.
11. Grotz AA, Henneicke-von Zepelin HH, Khnen R, et al (1999). Prospective double-blind study of radioxerostomia with coumarin/troxerutine in patients with head and neck cancer. Strahlenther Onkol, 175, 397-404.
12. Gueguen-Duchesne M, Durand F, Le Goff MC, et al (1988). Effects of troxerutin on the hemorhhological parameters of patients with moderate arterial hypertension. Prog Clin Biol Res Centre, 280, 401-6.
13. Hladovec J (1986). Antithrombotics in view of thrombosis models. Thromb Res, 43, 545-61.
14. Hosseinimehr SJ (2007). Foundation review: Trends in the development of radioprotective agents. Drug Discov Today, 12, 794-805.
15. Incandela L, De Sanctis MT, Cesarone MR, et al (1996). Efficacy of troxerutin in patients with chronic venous insufficiency: a double-blind, placebo-controlled study. Adv Ther, 13, 161-6.
16. Krupinski K, Giedrojc J, Bielawiec M (1996). Effect of troxerutin on laser-induced thrombus formation in rat mesenteric vessels, coagulation parameter and platelet function. Pol J Pharmacol, 48, 335-9.
17. Kessler M, Ubeaud G, Walter T, et al (2002). Free radical scavenging and skin penetration on troxerutin and vitamin derivatives. Dermatolog Treat, 13, 133-41.
18. Maunch P, Constine L, Greenberger J, et al (1995). Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Rad Oncol Biol Phys, 31, 1319-39.
19. Nair CKK, Parida DK, Nomura T (2001). Radioprotectors in radiotherapy. J Radiat Res, 42, 21-37.
20. Rehn D, Brunnauer H, Diebschlag W (1996). Investigation of the therapeutic equivalence of different galenical preparations of O-(beta-hydroxyethyl)-rutosides following multiple dose peroral administration. Arztl Forsch, 46, 488-92.
21. Rehn D, Golden G, Nocker W, et al (1993). Comparision between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency. Arzneimittelforschung, 43, 1060-3.
22. Schuller-Petrovic S, Wolzt M, Bohler K, et al (1994). Studies on the effect of short-term oral dihydroergotamine and troxerutin in patients with varicose veins. Clin Pharmacol Ther, 56, 452-9.
23. Umadevi P (1998). Normal tissue protection in cancer therapy: progress and prospects. Acta Oncol, 37, 247-51.
24. Vanscheidt W, Rabe E, Naser-Hijazi B, et al (2002). The efficacy and safety of a coumarin-/troxerutin-combination (SB-LOT) in patients with chronic venous insufficiency: a double blind placebo-controlled randomized study. Vasa, 31, 185-90.
25. Vin F, Chabanel A, Taccoen A, et al (1992). Action of the troxerutin on clinical parameters, plethysmographics and rheologics of venous insufficiency of the lower limbs: A placebo controled trial. Arteres Veines, 11, 333-42.
26. Vin F, Chabanel A, Taccoen A, et al (1994). Double blind trial of the efficacy of troxerutin in chronic venous insufficiency. Phlebologie, 9, 71-8.
27. Weiss JF (1997). Pharmacological approaches to protection against radiation induced lethality and other damages. Environ. Health Perspect, 105, 1473-8.
28. Weiss JF, Landauer MR (2009). History and development of radiation-protective agents. Int J Radiat Biol, 85, 539-73.
29. Wadworth A, Faulds D (1992). A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders. Drugs, 44, 1013-32.
30. Wenisch C (2001). Effect of bioflavonoids (trihydroxyethylrutin and disodium flavodate) in vitro on neutrophil reactive oxygen production and phagocytotic ability to assessed by flow cytometry. Curr Med Res Opan, 17, 123-7.
31. Xu SY, Bian RL and Chen X (2003). Pharmacology Experimental Methodology. Beijing: People's Medical Publishing House.